CTCBIO Inc. (KOSDAQ:060590)
South Korea · Delayed Price · Currency is KRW 2,595.00
-80.00 (-2.99%)
At close: Nov 6, 2026
CTCBIO Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 131,539 | 123,769 | 119,877 | 137,878 | 165,206 | 140,318 |
Revenue Growth | 17.21% | 3.25% | -13.06% | -16.54% | 17.74% | 7.91% |
Gross Profit Gross Profit Growth | 52,758 | 49,959 | 49,232 | 42,570 | 54,056 | 33,090 |
Operating Income Operating Income Growth | 11,349 | 6,250 | -5,014 | -4,578 | 11,230 | -2,938 |
Net Income Net Income Growth | 7,513 | 3,241 | -5,220 | -15,588 | 4,704 | -7,318 |
Earnings Per Share EPS Growth | 313.54 | 135.54 | -218.35 | -652.00 | 197.00 | -329.29 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Animal and Human Medicines and Health Functional Foods Animal and Human Medicines and Health Functional Foods Growth | 143,324 | 135,582 | 128,488 | - | - | - |
Consolidation Adjustments Consolidation Adjustments Growth | -11,785 | -11,812 | -8,611 | -5,254 | -8,596 | -3,741 |
Total Total Growth | 131,539 | 123,769 | 119,877 | 137,878 | 165,206 | 140,318 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 22,827 | 17,711 | 19,171 | 24,679 | 24,351 | 7,695 |
Total Debt Total Debt Growth | 40,333 | 38,743 | 32,870 | 35,289 | 39,958 | 40,656 |
Net Cash (Debt) Net Cash Growth | -17,506 | -21,032 | -13,698 | -10,610 | -15,607 | -32,961 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -732.21 | -879.69 | -572.94 | -443.76 | -655.27 | -1483.12 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 8,736 | 4,383 | 4,496 | 8,216 | 18,224 | 6,457 |
Capital Expenditures CapEx Growth | -1,549 | -786.53 | -2,139 | -1,885 | -3,173 | -1,674 |
Free Cash Flow Free Cash Flow Growth | 7,187 | 3,597 | 2,357 | 6,331 | 15,051 | 4,783 |
Free Cash Flow Growth | -5.69% | 52.60% | -62.77% | -57.94% | 214.66% | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 40.11% | 40.37% | 41.07% | 30.88% | 32.72% | 23.58% |
Operating Margin | 8.63% | 5.05% | -4.18% | -3.32% | 6.80% | -2.09% |
Pretax Margin | 6.64% | 2.41% | -4.43% | -11.40% | 0.12% | -5.48% |
Profit Margin | 5.71% | 2.62% | -4.35% | -11.31% | 2.85% | -5.21% |
FCF Margin | 5.46% | 2.91% | 1.97% | 4.59% | 9.11% | 3.41% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.28 | 34.12 | - | - | 32.02 | - |
P/FCF Ratio | 8.90 | 30.75 | 66.44 | 40.41 | 10.01 | 44.23 |
PS Ratio | 0.49 | 0.89 | 1.31 | 1.86 | 0.91 | 1.51 |